Thiogenesis Therapeutics, Corp.

TORONTO, A6 · Founded 2018 · CIK 0001877778 · Biotech · Public

Sulfur-based thiol compounds (TTI-0102) for mitochondrial disease treatment

thiogenesis.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$878K
5 Form D · Jun 2026
4 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$252,756
Private capital raisedForm D · SEC$218,303
Private capital raisedForm D · SEC$252,281
Private capital raisedForm D · SEC$125,450
Private capital raisedForm D · SEC$28,964
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2574MATINAS BIOPHARMA, INC.—$1.0M
2575CURIS INC—$964K
2576SUMOCOR, LLC——
2577Thiogenesis Therapeutics, Corp.—$878K
2578Gradient Pharmaceuticals, Inc.—$850K
2579Chemistry Holdings, Inc.—$845K
2580SOUTHEAST TECHINVENTURES, INC.—$836K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Neil JohnsonDirector · Executive Officer
  • Hogan MullallyDirector
  • W. Hogan MullallyDirector
  • Brook RigginsDirector · Executive Officer
  • Patrice RiouxDirector · Executive Officer
  • Christopher StarrDirector
  • Kim TsuchimotoDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.